Literature DB >> 9973435

A transgenic model to analyze the immunoregulatory role of IL-10 secreted by antigen-presenting cells.

H Groux1, F Cottrez, M Rouleau, S Mauze, S Antonenko, S Hurst, T McNeil, M Bigler, M G Roncarolo, R L Coffman.   

Abstract

IL-10 is a cytokine secreted by a wide variety of cells type that has pleiotropic stimulatory and suppressive activities on both lymphoid and myeloid cells in vitro. To analyze the consequences of high IL-10 secretion by APCs in immune responses, we produced transgenic mice expressing human IL-10 directed by the MHC class II Ea promoter. Despite alterations in the development of T and B cells, no gross abnormalities were detected in peripheral lymphocyte populations or serum Ig levels. However, when immunized using conditions that give either a Th2-type or a Th1-type response, IL-10 transgenic mice failed to mount a significant T or B cell immune response to OVA. IL-10 transgenic mice were also highly susceptible to infection with intracellular pathogens like Listeria monocytogenes or Leishmania major, in contrast to IL-10 transgenic mice, where the transgene was express in T cells. Finally, the recently described stimulatory effect of IL-10 on CD8+ T cells was confirmed by the ability of IL-10 transgenic mice to limit the growth of immunogenic tumors by a CTL-mediated mechanism. These results demonstrate, that, depending on the type of immune response, IL-10 can mediate immunosuppressive or immunostimulatory activities in vivo.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9973435

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  68 in total

1.  Interleukin 10 treatment for rheumatoid arthritis.

Authors:  E W St Clair
Journal:  Ann Rheum Dis       Date:  1999-11       Impact factor: 19.103

Review 2.  Th1/Th2 balance in cancer, transplantation and pregnancy.

Authors:  M R Shurin; L Lu; P Kalinski; A M Stewart-Akers; M T Lotze
Journal:  Springer Semin Immunopathol       Date:  1999

3.  Increased apoptosis of CD20+ IgA + B cells is the basis for IgA deficiency: the molecular mechanism for correction in vitro by IL-10 and CD40L.

Authors:  Zaheed Husain; Nichol Holodick; Caitlin Day; Irma Szymanski; Chester A Alper
Journal:  J Clin Immunol       Date:  2006-04-26       Impact factor: 8.317

4.  Induction of tumor immunity and cytotoxic t lymphocyte responses using dendritic cells transduced by adenoviral vectors encoding HBsAg: comparison to protein immunization.

Authors:  Shuang-Jian Qiu; Lina Lu; Chunping Qiao; LiangFu Wang; Zhong Wang; Xiao Xiao; Shiguang Qian; John J Fung; Sheng-Long Ye; C Andrew Bonham
Journal:  J Cancer Res Clin Oncol       Date:  2005-04-08       Impact factor: 4.553

Review 5.  Persistent parasites and immunologic memory in cutaneous leishmaniasis: implications for vaccine designs and vaccination strategies.

Authors:  Ifeoma Okwor; Jude Uzonna
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

6.  Key role of macrophages in tolerance induction via T regulatory type 1 (Tr1) cells.

Authors:  B Mfarrej; T Jofra; C Morsiani; N Gagliani; G Fousteri; M Battaglia
Journal:  Clin Exp Immunol       Date:  2020-05-13       Impact factor: 4.330

7.  IL-27 enhances the survival of tumor antigen-specific CD8+ T cells and programs them into IL-10-producing, memory precursor-like effector cells.

Authors:  Zhenzhen Liu; Jin-Qing Liu; Fatemeh Talebian; Lai-Chu Wu; Shulin Li; Xue-Feng Bai
Journal:  Eur J Immunol       Date:  2013-01-15       Impact factor: 5.532

8.  Inducible transgenes under the control of the hCD68 promoter identifies mouse macrophages with a distribution that differs from the F4/80 - and CSF-1R-expressing populations.

Authors:  Manoj M Pillai; Brian Hayes; Beverly Torok-Storb
Journal:  Exp Hematol       Date:  2009-09-20       Impact factor: 3.084

Review 9.  Cell type-specific regulation of IL-10 expression in inflammation and disease.

Authors:  Christian M Hedrich; Jay H Bream
Journal:  Immunol Res       Date:  2010-07       Impact factor: 2.829

10.  PEG-rIL-10 treatment decreases FoxP3(+) Tregs despite upregulation of intratumoral IDO.

Authors:  Ivan H Chan; Victoria Wu; Melissa Bilardello; Brett Jorgenson; Harminder Bal; Scott McCauley; Peter Van Vlasselaer; John B Mumm
Journal:  Oncoimmunology       Date:  2016-06-27       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.